Bristol OTC migraine labeling study shows "superficial" comprehension -- FDA's Lechter.
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL-MYERS LABELING STUDY SHOWS "SUPERFICIAL" UNDERSTANDING of the proposed OTC migraine statements for Excedrin Extra Strength, FDA Division of Drug Marketing, Advertising & Communications Social Science Analyst Karen Lechter, PhD, commented at a July 15 FDA advisory committee meeting. "Potential users who are probable migraine sufferers seem to understand the migraine-specific elements of the label," but that understanding "was at a rather superficial level," Lechter said.